Checked.be
Active
BE 0671.904.152Private limited company
COLE PHARMACEUTICALS
Rue André Dumont 7 ·1435 Mont-Saint-Guibert, Belgium· 9 yrs active
Sector: Groothandel in farmaceutische en medische artikelen
(46460)
Conclusion
The computed 12-month bankruptcy probability of COLE PHARMACEUTICALS is 0.8% (low). The company has been active since 2017 and the Belgian State Gazette contains no insolvency or warning signals. No processed annual-account figures are available; this conclusion rests on registry and State Gazette data only.
Based on State Gazette and CBE data.
Key figures
| Active | 9 yrs |
| Board | 2 |
| Locations | 1 |
| Publications | 10 |
Bankruptcy probability (12 mo)
0.8%
Low
0%0,5%1,5%4%10%≥25%
Higher-failure-rate sector
+Higher-failure-rate region
+
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Risk Assessment
0 / 100
Low riskTrust signals
More than 3 years active
Founded in 2017, past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Financial overview
Financials being processed
NBB has 8 filing(s) on record for this company, latest fiscal year 2024 (micro). The annual accounts are being processed.
Filings on record
| Fiscal year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2024 | micro | 16-07-2025 | 2025-00275717 |
| 31-12-2023 | micro | 24-03-2025 | 2025-00053960 |
| 31-12-2022 | micro | 31-08-2023 | 2023-00393619 |
| 31-12-2021 | micro | 26-08-2022 | 2022-20320786 |
| 31-12-2020 | micro | 27-08-2021 | 2021-55300206 |
| 31-12-2019 | micro | 31-08-2020 | 2020-51200366 |
| 31-12-2018 | micro | 29-08-2019 | 2019-56200562 |
| 31-12-2017 | micro | 28-08-2018 | 2018-53700353 |
Directors & mandates
Current directors & mandates
-
Current08-03-2021 → present
-
Current08-03-2021 → present
2 events
- 08-03-2021 Appointed· Director
- 18-01-2021 Resigned· Director
Former directors (1)
-
Former- → 13-06-2017
Full appointment history from the Belgian State Gazette. Permanent representatives are shown for corporate directors.
Statutory auditor
| Statutory auditor | IRE/IBR number | Tenure |
|---|---|---|
| Adil El FilaliCurrent Statutory auditor |
- | 24-07-2023 → present |
Appointed statutory auditor from the Belgian State Gazette. The IRE/IBR number refers to the register of the Institute of Registered Auditors.
Legal Structure
| NACE primary | Groothandel in farmaceutische en medische artikelen(46460) |
| Legal form | Private limited company(610) |
| Incorporation | 28-02-2017 |
| Status | Active |
| Postal code | 1435 |
Connections & network
Network connections
Shared address
→
Connections derived from shared directors, addresses, shareholders and group structure in the Belgian State Gazette.
Establishment units
Cole Pharma
since 20172.262.091.864
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Updates
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
2026
08-06-2026
State Gazette act
Open capture
2025
16-07-2025
NBB filing
Annual accounts filed
24-03-2025
NBB filing
Annual accounts filed
2024
29-11-2024
State Gazette act
Registered-office change
2023
25-09-2023
State Gazette act
Capital & shares
31-08-2023
NBB filing
Annual accounts filed
24-07-2023
State Gazette act
Director changes
2022
26-08-2022
NBB filing
Annual accounts filed
10-06-2022
State Gazette act
Statutes amendment
2021
27-08-2021
NBB filing
Annual accounts filed
22-04-2021
State Gazette act
Director changes
08-03-2021
State Gazette act
Director changes
2020
31-08-2020
NBB filing
Annual accounts filed
10-01-2020
State Gazette act
Capital & shares
2019
29-08-2019
NBB filing
Annual accounts filed
2018
28-08-2018
NBB filing
Annual accounts filed
2017
06-07-2017
State Gazette act
Capital & shares
02-03-2017
State Gazette act
Incorporation
Belgisch Staatsblad, acts
Capital history · 4
08-06-2026
Capital increase: amount: 1589000, currency: EUR, share_class: D, share_premium: 0, shares_issued: 659549
25-09-2023
v3.2
10-01-2020
v3.2
06-07-2017
v3.2
Address history · 1
29-11-2024
v3.2
All acts · 10
updated 2 months ago
2026
08-06-2026 General meeting · Notarial deed · Auditor waiver · Auditor report
- Filing: 2026-05-28 · COLE PHARMACEUTICALS
- Publication: 2026-06-08 · COLE PHARMACEUTICALS
- General meeting: 2025-12-23 · COLE PHARMACEUTICALS
- Notarial deed: 2025-12-23 · COLE PHARMACEUTICALS
- Auditor waiver · COLE PHARMACEUTICALS
- Auditor report · COLE PHARMACEUTICALS
- Approval · COLE PHARMACEUTICALS
- Capital increase: amount: 1589000, currency: EUR, share_class: D, share_premium: 0, shares_issued: 659549 · COLE PHARMACEUTICALS
- Share distribution: class: D, shares: 35088 · COLE PHARMACEUTICALS
- Share distribution: class: D, shares: 2105 · COLE PHARMACEUTICALS
- Share distribution: class: D, shares: 92184 · COLE PHARMACEUTICALS
- Share distribution: class: D, shares: 90113 · COLE PHARMACEUTICALS
- Share distribution: class: D, shares: 60172 · COLE PHARMACEUTICALS
- Share distribution: class: D, shares: 111586 · COLE PHARMACEUTICALS
- Share distribution: class: D, shares: 268301 · COLE PHARMACEUTICALS
- Statute amendment · COLE PHARMACEUTICALS
- Governance rule · COLE PHARMACEUTICALS
- Reserve release · COLE PHARMACEUTICALS
- Act object: Apports en nature - Modification des statuts
Summary:
General meeting · Notarial deed · Auditor waiver · Auditor report
Technical details
{
"facts": [
{
"type": "filing",
"quote": "TRIBUNAL DE L\u0027ENTREPRISE 28 MAI 2026",
"value": "2026-05-28",
"object": null,
"subject": "e1"
},
{
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 08/06/2026 - Annexes du Moniteur belge",
"value": "2026-06-08",
"object": null,
"subject": "e1"
},
{
"type": "general_meeting",
"quote": "D\u0027un proc\u00E8s-verbal d\u0027assembl\u00E9e g\u00E9n\u00E9rale extraordinaire dress\u00E9 par le notaire Laurent WETS, \u00E0 Uccle, le 23 d\u00E9cembre 2025",
"value": "2025-12-23",
"object": null,
"subject": "e1"
},
{
"type": "notarial_deed",
"quote": "D\u0027un proc\u00E8s-verbal d\u0027assembl\u00E9e g\u00E9n\u00E9rale extraordinaire dress\u00E9 par le notaire Laurent WETS, \u00E0 Uccle, le 23 d\u00E9cembre 2025",
"value": "2025-12-23",
"object": "e2",
"subject": "e1"
},
{
"type": "auditor_waiver",
"quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale a dispens\u00E9 le Pr\u00E9sident de donner lecture du rapport \u00E9tabli par l\u0027organe d\u0027administration, le 15 d\u00E9cembre 2025",
"value": null,
"object": null,
"subject": "e1"
},
{
"type": "auditor_report",
"quote": "Le rapport du R\u00E9viseur d\u0027entreprises, Monsieur DEMONCEAU David, exer\u00E7ant sa fonction dans la Soci\u00E9t\u00E9 \u00E0 Responsabilit\u00E9 Limit\u00E9e \u003C AXYLIUM AUDIT - LIEGE \u00BB",
"value": null,
"object": "e4",
"subject": "e1"
},
{
"type": "approval",
"quote": "L\u0027assembl\u00E9e a approuv\u00E9 ces deux rapports.",
"value": null,
"object": null,
"subject": "e1"
},
{
"type": "capital_increase",
"quote": "L\u0027op\u00E9ration consiste en une augmentation des capitaux propres de 1.589.000 \u20AC par apports de cr\u00E9ances et de droits de propri\u00E9t\u00E9 intellectuelle",
"value": {
"amount": 1589000,
"currency": "EUR",
"share_class": "D",
"share_premium": 0,
"shares_issued": 659549
},
"object": null,
"subject": "e1"
},
{
"type": "share_distribution",
"quote": "1. A La Soci\u00E9t\u00E9 \u00E0 Responsabilit\u00E9 Limit\u00E9e \u003C Sodintec Finances \u00BB, pr\u00E9cit\u00E9e, qui a d\u00E9clar\u00E9 accepter, trente-cing mille quatre-vingt-huit actions, ci: 35.088",
"value": {
"class": "D",
"shares": 35088,
"consideration": {
"type": "cr\u00E9ances",
"amount": 60000,
"currency": "EUR"
}
},
"object": "e6",
"subject": "e1"
},
{
"type": "share_distribution",
"quote": "2. A La Soci\u00E9t\u00E9 \u00E0 Responsabilit\u00E9 Limit\u00E9e \u00AB Spreds Finance \u003E, qui a d\u00E9clar\u00E9 accepter, deux mille cent cing cents actions, ci: 2.105",
"value": {
"class": "D",
"shares": 2105,
"consideration": {
"type": "cr\u00E9ances",
"amount": 4760,
"currency": "EUR"
}
},
"object": "e7",
"subject": "e1"
},
{
"type": "share_distribution",
"quote": "3. A la Soci\u00E9t\u00E9 Anonyme \u003C C\u0026N Holding \u00BB, pr\u00E9cit\u00E9e, qui a d\u00E9clar\u00E9 accepter, nonante-deux mille cent quatre-vingt-quatre actions, ci: 92.184",
"value": {
"class": "D",
"shares": 92184,
"consideration": {
"type": "cr\u00E9ances",
"amount": 200000,
"currency": "EUR"
}
},
"object": "e8",
"subject": "e1"
},
{
"type": "share_distribution",
"quote": "4. A Monsieur DELEUZE St\u00E9phane, pr\u00E9nomm\u00E9, qui a d\u00E9clar\u00E9 accepter, nonante mille cent treize actions, ci : 90.113",
"value": {
"class": "D",
"shares": 90113,
"consideration": {
"type": "cr\u00E9ances",
"amount": 200000,
"currency": "EUR"
}
},
"object": "e9",
"subject": "e1"
},
{
"type": "share_distribution",
"quote": "5. A Monsieur B\u00C9NARD Andr\u00E9, pr\u00E9nomm\u00E9, qui a d\u00E9clar\u00E9 accepter, soixante mille cent soixante-deux actions, ci: 60.172",
"value": {
"class": "D",
"shares": 60172,
"consideration": {
"type": "cr\u00E9ances",
"amount": 150000,
"currency": "EUR"
}
},
"object": "e10",
"subject": "e1"
},
{
"type": "share_distribution",
"quote": "6. A Monsieur PHILIPS Mario, pr\u00E9nomm\u00E9, qui a d\u00E9clar\u00E9 accepter, cent onze mille cing cent quatre-vingt-six (111.586) actions, ci: 111.586",
"value": {
"class": "D",
"shares": 111586,
"consideration": {
"type": "cr\u00E9ances",
"amount": 200000,
"currency": "EUR"
}
},
"object": "e11",
"subject": "e1"
},
{
"type": "share_distribution",
"quote": "7. A la Soci\u00E9t\u00E9 Anonyme Phytomed, pr\u00E9cit\u00E9e, qui a d\u00E9clar\u00E9 accepter, deux cent soixante-huit mille trois cent une actions, ci: 268.301",
"value": {
"class": "D",
"shares": 268301,
"consideration": {
"type": "droits de propri\u00E9t\u00E9 intellectuelle",
"amount": 775000,
"currency": "EUR"
}
},
"object": "e12",
"subject": "e1"
},
{
"type": "statute_amendment",
"quote": "l\u0027assembl\u00E9e g\u00E9n\u00E9rale a d\u00E9clar\u00E9 et d\u00E9cid\u00E9 de remplacer les articles 5, 7 et 11 des statuts par les textes suivants",
"value": null,
"object": null,
"subject": "e1"
},
{
"type": "governance_rule",
"quote": "l\u0027assembl\u00E9e g\u00E9n\u00E9rale a d\u00E9cid\u00E9 de pr\u00E9voir, dans les statuts, la d\u00E9l\u00E9gation \u00E0 l\u0027organe d\u0027administration du pouvoir de proc\u00E9der, dans les limites des articles 5:142 et 5:143 dudit Code \u00E0 des distributions provenant du b\u00E9n\u00E9fice de l\u0027exercice en cours ou du b\u00E9n\u00E9fice de l\u0027exercice pr\u00E9c\u00E9dent tant que les comptes annuels de cet exercice n\u0027ont pas \u00E9t\u00E9 approuv\u00E9s",
"value": null,
"object": null,
"subject": "e1"
},
{
"type": "reserve_release",
"quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale a d\u00E9cid\u00E9 de transf\u00E9rer la totalit\u00E9 des pertes report\u00E9es au compte apports disponibles.",
"value": null,
"object": null,
"subject": "e1"
},
{
"type": "act_object",
"quote": "Objet de l\u0027acte: Apports en nature - Modification des statuts",
"value": "Apports en nature - Modification des statuts",
"object": null,
"subject": null
}
],
"act_meta": {
"model_id": 40,
"extractor": "open-capture-27b-v3",
"ocr_chars": 18831,
"truncated": false,
"needs_verify": true
},
"entities": [
{
"id": "e1",
"kbo": "0671.904.152",
"kind": "company",
"name": "COLE PHARMACEUTICALS",
"attrs": {
"vat": "BE0671.904.152",
"seat": "1435 Mont-Saint-Guibert, Rue Andr\u00E9 Dumont, 7",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 Responsabilit\u00E9 Limit\u00E9e",
"short_name": "Cole Pharma"
}
},
{
"id": "e2",
"kbo": null,
"kind": "person",
"name": "Laurent WETS",
"attrs": {
"role": "notaire"
}
},
{
"id": "e3",
"kbo": null,
"kind": "person",
"name": "V\u00E9ronique Bonehill",
"attrs": {
"role": "notaire"
}
},
{
"id": "e4",
"kbo": null,
"kind": "person",
"name": "DEMONCEAU David",
"attrs": {
"role": "R\u00E9viseur d\u0027entreprises"
}
},
{
"id": "e5",
"kbo": null,
"kind": "org",
"name": "AXYLIUM AUDIT - LIEGE",
"attrs": {
"legal_form": "Soci\u00E9t\u00E9 \u00E0 Responsabilit\u00E9 Limit\u00E9e"
}
},
{
"id": "e6",
"kbo": "0507.657.517",
"kind": "company",
"name": "Sodintec Finances",
"attrs": {
"vat": "BE0507.657.517",
"seat": "1200 Woluwe-Saint-Lambert Bruxelles, Rue Lola Bobesco, 2, bo\u00EEte 13",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 Responsabilit\u00E9 Limit\u00E9e"
}
},
{
"id": "e7",
"kbo": "0538.839.354",
"kind": "company",
"name": "Spreds Finance",
"attrs": {
"vat": "BE0538.839.354",
"seat": "1000 Bruxelles, Rue des Colonies, 11",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 Responsabilit\u00E9 Limit\u00E9e"
}
},
{
"id": "e8",
"kbo": "0866.337.880",
"kind": "company",
"name": "C\u0026N Holding",
"attrs": {
"vat": "BE0866.337.880",
"seat": "1910 Kampenhout, Terloonststraat, 22",
"legal_form": "Soci\u00E9t\u00E9 Anonyme"
}
},
{
"id": "e9",
"kbo": null,
"kind": "person",
"name": "DELEUZE St\u00E9phane Camille Paul Arthur",
"attrs": {
"domicile": "London (Royaume-Uni-Grande Bretagne), Lawn Lane, 10, Apartment 1"
}
},
{
"id": "e10",
"kbo": null,
"kind": "person",
"name": "B\u00C9NARD Andr\u00E9 Marcel Victor",
"attrs": {
"domicile": "Woluwe-Saint-Pierre (1150 Bruxelles), Avenue des Cormorans, 38"
}
},
{
"id": "e11",
"kbo": null,
"kind": "person",
"name": "PHILIPS Mario",
"attrs": {
"domicile": "9340 Lede, Erfken, 6"
}
},
{
"id": "e12",
"kbo": "1031.897.777",
"kind": "company",
"name": "Phytomed",
"attrs": {
"vat": "BE 1031.897.777",
"seat": "9911 Troisvierges (Grand-Duch\u00E9 du Luxembourg), Rue de Drinklange, 2",
"rcs_lux": "B184202",
"legal_form": "Soci\u00E9t\u00E9 Anonyme de droit luxembourgeois"
}
}
]
}2024
29-11-2024 Registered office moved from Grez-Doiceau to Mont-Saint-Guibert
- Champ de Maubroux 21, 1390 Grez-Doiceau → rue André Dumont 7, 1435 Mont-Saint-Guibert
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "statutaire",
"new_address": {
"city": "Mont-Saint-Guibert",
"region": null,
"street": "rue Andr\u00E9 Dumont",
"country": "BE",
"postcode": "1435",
"box_number": null,
"street_number": "7"
},
"old_address": {
"city": "Grez-Doiceau",
"region": null,
"street": "Champ de Maubroux",
"country": "BE",
"postcode": "1390",
"box_number": null,
"street_number": "21"
},
"effective_date": "2024-11-12",
"evidence_quote": "Le conseil d\u0027administration d\u00E9cide de transf\u00E9rer \u00E0 dater de ce jour le si\u00E8ge de la Soci\u00E9t\u00E9 \u00E0 l\u0027adresse suivante: rue Andr\u00E9 Dumont 7, 1435 Mont-Saint- Guibert."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0671.904.152",
"name_full": "COLE PHARMACEUTICALS, EN ABREGE : COLE PHARMA",
"legal_form": "SRL"
}
}2023
25-09-2023 Capital increase of €581,409.84
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 581409.84,
"currency": "EUR",
"after_eur": null,
"delta_eur": 581409.84,
"before_eur": null,
"amount_type": "kapitaal_effectief",
"effective_date": "2023-08-30",
"evidence_quote": "Total apport 581.409,84",
"contribution_type": "in_kind"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0671.904.152",
"name_full": "COLE PHARMACEUTICALS, EN ABREGE : COLE PHARMA",
"legal_form": "SRL"
}
}24-07-2023 Adil El Filali appointed as statutory auditor
- Adil El Filali, Commissaris
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "commissaris_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Adil El Filali",
"address": null,
"birth_date": null
},
"evidence_quote": "Le conseil propose la nomination de M. Adil El Filali, Reviseur d\u0027entreprise associ\u00E9-fondateur du bureau CLC SRL (Contr\u00F4le L\u00E9gal des Comptes \u0026 Consultance), comme commissaire aux comptes avec un mandat de 3 ans. L\u0027assembl\u00E9e approuve ces deux propositions \u00E0 l\u0027unanimit\u00E9 des voix."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0671.904.152",
"name_full": "COLE PHARMACEUTICALS, EN ABREGE : COLE PHARMA",
"legal_form": "SRL"
}
}2022
10-06-2022 Articles of association amended
Summary:
v3.2
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2022-06-10",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0671.904.152",
"name_full": "COLE PHARMACEUTICALS, EN ABREGE : COLE PHARMA",
"legal_form": "SRL"
},
"signature_regime": null,
"special_mandates": [],
"governance_change": {
"admin_delegated_added": []
}
}2021
22-04-2021 Marío Philips resigns as director
- Marío Philips, Bestuurder
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Mar\u00EDo Philips",
"address": null,
"birth_date": null
},
"effective_date": "2021-01-18",
"evidence_quote": "Le conseil d\u0027administartion acte la d\u00E9mission, \u00E0 dater du 18 janvier 2021, de Mr Mar\u00EDo Philips"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0671.904.152",
"name_full": "COLE PHARMACEUTICALS, EN ABREGE : COLE PHARMA",
"legal_form": "SRL"
}
}08-03-2021 2 directors appointed
- Mario Philips, Bestuurder
- Guillaume de Viron, Bestuurder
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Mario Philips",
"address": null,
"birth_date": null
},
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale nomme en tant qu\u0027administrateur pour une dur\u00E9e de 3 ans: - Mr Mario Philips domicili\u00E9 Erfken, 6 \u00E0 9340 Lede n\u00E9 le 17 juillet 1969 \u00E0 Aalst (n.n.69.07.17-427-76)"
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Guillaume de Viron",
"address": null,
"birth_date": null
},
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale nomme en tant qu\u0027administrateur pour une dur\u00E9e de 3 ans: ... - Mr Guillaume de Viron domicili\u00E9 Chemin du Bois de Villers, 8b \u00E0 1325 Chaumonx-Gistoux, n\u00E9 le 27 ao\u00FBt 1977 \u00E0 Ixelles (n.n. 77.08.25-211.33)"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0671.904.152",
"name_full": "COLE PHARMACEUTICALS, EN ABREGE : COLE PHARMA",
"legal_form": "SRL"
}
}2020
10-01-2020 Capital increase of €438,400 to €457,000
- €18.600 → €457.000
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 438400.0,
"currency": "EUR",
"after_eur": 457000.0,
"delta_eur": 438400.0,
"before_eur": 18600.0,
"amount_type": "kapitaal_effectief",
"effective_date": "2019-12-23",
"evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide d\u0027augmenter le capital, \u00E0 concurrence de quatre cent trente-huit mille quatre cents euros (438.400,00.EUR), pour le porter de dix-huit mille six cents euros (18.600,00.EUR), \u00E0 quatre cent cinquante-sept mille euros (457.000,00.EUR), par la cr\u00E9ation de quatre cent trente-huit mille quatre cents parts sociales nouvelles... Ces parts nouvelles seront imm\u00E9diatement souscrites en esp\u00E8ces et enti\u00E8rement lib\u00E9r\u00E9es \u00E0 la souscription.",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0671.904.152",
"name_full": "COLE PHARMACEUTICALS, EN ABREGE : COLE PHARMA",
"legal_form": "SPRL"
}
}2017
06-07-2017 Transaction in capital or shares
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "share_transfer",
"amount": 62,
"currency": null,
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"amount_type": "onbekend",
"effective_date": "2017-06-13",
"evidence_quote": "Monsieur Giovanni NAVALESI c\u00E8de ses 62 parts sociales \u00E0 Monsieur Claude LUBICKI (31 parts) et \u00E0 Monsieur Jean-Marie VANDEPLAS (31 parts).",
"contribution_type": null
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0671.904.152",
"name_full": "COLE PHARMACEUTICALS, EN ABREGE : COLE PHARMA",
"legal_form": "SPRL"
}
}02-03-2017 Incorporation of a new SNC
Summary:
oprichting
Technical details
{
"kind": "oprichting",
"seat": "Avenue Lat\u00E9rale 143 bte A 10, 1180 Uccle",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": null,
"kind": "natural_person",
"person": {
"dob": "1956-03-06",
"name": "VANDEPLAS Jean-Marie Fernand Joseph",
"niss": null,
"address": "1390 Grez-Doiceau, Champ de Maubroux, 21"
},
"share_class": "ordinary",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": null,
"contribution_type": "cash",
"amount_paid_in_eur": 3100,
"holder_person_name": "VANDEPLAS Jean-Marie Fernand Joseph",
"is_subscriber_only": false,
"n_shares_subscribed": 62,
"amount_subscribed_eur": 6200,
"is_anonymous_silent_partner": false
},
{
"org": null,
"kind": "natural_person",
"person": {
"dob": "1960-05-25",
"name": "LUBICKI Claude",
"niss": null,
"address": "Uccle (1180 Bruxelles), Avenue Lat\u00E9rale, 143 \u2013 A10"
},
"share_class": "ordinary",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": null,
"contribution_type": "cash",
"amount_paid_in_eur": 3100,
"holder_person_name": "LUBICKI Claude",
"is_subscriber_only": false,
"n_shares_subscribed": 62,
"amount_subscribed_eur": 6200,
"is_anonymous_silent_partner": false
},
{
"org": null,
"kind": "natural_person",
"person": {
"dob": "1959-03-28",
"name": "NAVALESI Giovanni",
"niss": null,
"address": "Firenze (Italie), Via Reginaldo Giuliani, 287"
},
"share_class": "ordinary",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": null,
"contribution_type": "cash",
"amount_paid_in_eur": 3100,
"holder_person_name": "NAVALESI Giovanni",
"is_subscriber_only": false,
"n_shares_subscribed": 62,
"amount_subscribed_eur": 6200,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 18600,
"subject_company": {
"kbo": "0671.904.152",
"name_full": "COLE PHARMACEUTICALS",
"legal_form": "SNC"
},
"initial_directors": [],
"incorporation_date": "2017-02-27",
"post_incorporation_mandates": []
}Credit advice
AI due-diligence brief
Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
Coming soon
The brief is drafted by our AI model at Anthropic in the US, from this dossier's public data. Nothing that identifies you is sent along and we do not keep the brief. Indicative, not legal or investment advice. How it works
Company registry (CBE)
Activities
Groothandel in farmaceutische producten46460Groothandel in farmaceutische en medische artikelen46460Handelsbemiddeling in meubelen, huishoudelijke artikelen en ijzerwaren46150Handelsbemiddeling in de groothandel in meubelen, huishoudelijke artikelen en ijzerwaren46150
Primary activity highlighted.
Names & trade names
| Legal nameFR | COLE PHARMACEUTICALS |
| AbbreviationFR | Cole Pharma |
Registered office
Rue André Dumont 7
1435 Mont-Saint-Guibert, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.
Similar companies
APIX
BE 0755.327.023 · Mont-Saint-Guibert
BESCAN
BE 0650.630.567 · Mont-Saint-Guibert
CELYNTRA THERAPEUTICS
BE 0737.829.015 · Mont-Saint-Guibert
LOUPI MEDICAL BELGIUM
BE 0799.500.625 · Mont-Saint-Guibert
PUGH & CO INTERNATIONAL
BE 0403.086.171 · Mont-Saint-Guibert